Welcome to our dedicated page for Nasus Pharma Ltd. news (Ticker: NSRX), a resource for investors and traders seeking the latest updates and insights on Nasus Pharma Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nasus Pharma Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nasus Pharma Ltd.'s position in the market.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has successfully completed its Initial Public Offering (IPO). The company raised $10 million in gross proceeds through the offering of 1,250,000 ordinary shares at $8.00 per share.
Trading commenced on the NYSE American exchange on August 13, 2025, under ticker NSRX. The underwriters have a 45-day option to purchase up to 187,500 additional shares. Proceeds will fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies, along with general corporate purposes.
Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced the pricing of its Initial Public Offering (IPO). The company is offering 1,250,000 ordinary shares at $8.00 per share, aiming to raise $10 million in gross proceeds.
The company has granted underwriters a 45-day option to purchase up to 187,500 additional shares. Trading will commence on NYSE American LLC on August 13, 2025, under the symbol "NSRX". The proceeds will primarily fund the development of their intranasal Epinephrine program, including manufacturing scale-up and Phase 2 studies.
FAQ
What is the current stock price of Nasus Pharma Ltd. (NSRX)?
